Compare TNL & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNL | LNTH |
|---|---|---|
| Founded | 1990 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.2B |
| IPO Year | N/A | 2015 |
| Metric | TNL | LNTH |
|---|---|---|
| Price | $68.47 | $61.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | $67.60 | ★ $74.17 |
| AVG Volume (30 Days) | 557.8K | ★ 1.0M |
| Earning Date | 10-22-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.28% | N/A |
| EPS Growth | ★ 3.11 | N/A |
| EPS | ★ 6.07 | 2.39 |
| Revenue | ★ $3,967,000,000.00 | $1,525,933,000.00 |
| Revenue This Year | $4.48 | $0.01 |
| Revenue Next Year | $4.31 | $1.24 |
| P/E Ratio | ★ $11.24 | $25.41 |
| Revenue Growth | ★ 3.60 | 1.95 |
| 52 Week Low | $37.77 | $47.25 |
| 52 Week High | $70.43 | $111.29 |
| Indicator | TNL | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 62.99 | 63.29 |
| Support Level | $67.40 | $57.44 |
| Resistance Level | $68.88 | $64.40 |
| Average True Range (ATR) | 1.43 | 2.17 |
| MACD | 0.19 | 0.65 |
| Stochastic Oscillator | 88.57 | 77.15 |
Travel+Leisure Co is a membership and leisure travel company. It provides hospitality services and travel products. The company operates in the segments of Vacation Ownership, which is the key revenue-driving segment, develops, markets and sells vacation ownership interests (VOIs) to individual consumers, provides consumer financing in connection with the sale of VOIs, and provides property management services at resorts, and Travel and Membership which operates a variety of travel businesses, including three vacation exchange brands, a home exchange network, travel technology platforms, travel memberships, and direct-to-consumer rentals. The majority of the revenue is earned from the United States.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.